Illumina rival says patent verdict may lead to competition sooner
A jury verdict invalidating one of Illumina’s DNA-sequencing patents may allow a rival to enter the US market at an earlier date, likely influencing ongoing antitrust litigation between both companies and possibly also the Federal Trade Commission's complaint against Illumina's tie-up with Grail.
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10